Tarceva Cleared By Japanese Regulators For NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Number of patients newly diagnosed with NSCLC in Japan was 85,000 in 2005, according to Roche/OSI.
You may also be interested in...
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.
Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK
Pfizer plans to use the positive Phase III data in adults 18-59 to expand use of the RSV vaccine.